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In the general population, excluding violent deaths, cancer is the first cause of mortality, reaching 24% of the total, followed by 
cardiovascular disease, accounting for 22%(2). Due to the advances in sanitary conditions and the use of antibiotics, currently 
infectious diseases account for only 5% of deaths. Similarly to what occurs with other diseases, both primary and secondary 
prevention as well as early detection, associated with increasingly more effective therapeutic approaches, constitute invaluable 
resources to the reduction of morbidity and mortality in neoplastic processes.
World statistics demonstrate that one among three individuals will develop some form of cancer at a certain moment of their 
lives, and the projections suggest that its incidence will increase dramatically, mainly in developed countries(6).
According to the Instituto Nacional do Câncer (INCA), approximately 518,510 cases of cancer were diagnosed in Brazil in 2012, 
including 257,870 men and 260,640 women, and approximately 200,000 people died due to some form of this disease.
These data become even more astounding when we bear in mind that cancer is one of the most ancient diseases that have 
afflicted mankind. Furthermore, approximately 20% of all cancers are related to an avoidable cause, namely obesity(3).
Accurately speaking, cancer is not one disease, but several diseases, which present a common characteristic: uncontrolled cell 
proliferation. 
The economic aspects linked with this group of diseases are also astonishing. The US National Cancer Institute has an annual 
budget of 5 billion dollars. It is estimated that it has invested over 90 billion dollars in research, prevention and cancer treatment 
since 1971(5). Moreover, pharmaceutical industries have allocated considerable resources for research into the development and 
feasibility of potential diagnostic and therapeutic agents in the oncologic area.
For some cancers, the mortality rate has diminished slighlty in the last five years. For example, prostate cancer mortality has 
decreased 3.3%, breast cancer 2.2% and lungs 1.6%, respectively. On the other hand, it has risen in some other cancers such as 
liver (2.2%) and pancreas (0.6%)(1).
The question that remains to be answered is: are we winning or losing this battle?
Doubtlessly, our knowledge about cancer has improved exponentially in the last decades. The use of modern technologic tools, 
including new concepts such as genomics, proteomics, metabolomics and epigenomics, has allowed a better understanding of 
cellular, molecular and genetic aspects of neoplastic processes. 
Despite these advances, grasping the primary cause of neoplastic processes still remains controversial. Until 1910’s, the known 
causes of human cancer were restricted to chemical products such as paraffin and some dyes, soot and smoke from chimneys 
or exposure to ionizing radiation, sadly demonstrated by Marie Curie’s leukemia. However, as these potential causes were 
insufficient to explain all cases, the infectious theory, more specifically the viral one, has remained tantalizing. 
Peyton Rous was responsible for the objective demonstration of this possibility. In 1910, he successfully transmitted a fusiform 
cell sarcoma from one hen to others in repeated generations, making sure that only cell free liquid would be inoculated(8). His 
data were corroborated and other researchers also obtained similar results, experimentally working with other animals and 
other forms of cancer. 
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The presence of viral agents in human tumors was demonstrated only in the 1930’s, though its causality relations remained 
obscure.
In 1962, the cover article from Life magazine suggested that cancer could be infectious, hence leading to predictable 
consequences such as the segregation of contaminated individuals, as it was recommended for tuberculosis patients(4).
In this issue of Brazilian Journal of Pathology and Laboratory Medicine (BJPLM), an appropriate review of acknowledged 
cancer causing viruses is presented, addressing oncogenesis mechanisms and the importance of laboratory medicine in this 
area of knowledge(7).
Although Rous’s initial studies were not properly appreciated at that time, in 1966 he was awarded the Nobel Prize of Physiology 
and Medicine. During his ceremony speech, manifesting the humility of true researchers, he declared that the virus theory of 
cancer still required further investigations and clarification(9).
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